1. Home
  2. FPAY vs AKTX Comparison

FPAY vs AKTX Comparison

Compare FPAY & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FPAY
  • AKTX
  • Stock Information
  • Founded
  • FPAY 2003
  • AKTX N/A
  • Country
  • FPAY United States
  • AKTX United States
  • Employees
  • FPAY N/A
  • AKTX 12
  • Industry
  • FPAY Diversified Commercial Services
  • AKTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • FPAY Consumer Discretionary
  • AKTX Health Care
  • Exchange
  • FPAY Nasdaq
  • AKTX Nasdaq
  • Market Cap
  • FPAY 28.7M
  • AKTX 41.8M
  • IPO Year
  • FPAY N/A
  • AKTX N/A
  • Fundamental
  • Price
  • FPAY $1.36
  • AKTX $1.27
  • Analyst Decision
  • FPAY Strong Buy
  • AKTX
  • Analyst Count
  • FPAY 2
  • AKTX 0
  • Target Price
  • FPAY $3.25
  • AKTX N/A
  • AVG Volume (30 Days)
  • FPAY 42.2K
  • AKTX 11.7K
  • Earning Date
  • FPAY 08-05-2025
  • AKTX 05-15-2025
  • Dividend Yield
  • FPAY N/A
  • AKTX N/A
  • EPS Growth
  • FPAY N/A
  • AKTX N/A
  • EPS
  • FPAY N/A
  • AKTX N/A
  • Revenue
  • FPAY $139,800,732.00
  • AKTX N/A
  • Revenue This Year
  • FPAY $16.58
  • AKTX N/A
  • Revenue Next Year
  • FPAY N/A
  • AKTX N/A
  • P/E Ratio
  • FPAY N/A
  • AKTX N/A
  • Revenue Growth
  • FPAY 19.51
  • AKTX N/A
  • 52 Week Low
  • FPAY $0.97
  • AKTX $0.85
  • 52 Week High
  • FPAY $2.37
  • AKTX $4.40
  • Technical
  • Relative Strength Index (RSI)
  • FPAY 55.04
  • AKTX 46.51
  • Support Level
  • FPAY $1.36
  • AKTX $1.20
  • Resistance Level
  • FPAY $1.44
  • AKTX $1.42
  • Average True Range (ATR)
  • FPAY 0.08
  • AKTX 0.08
  • MACD
  • FPAY 0.01
  • AKTX -0.00
  • Stochastic Oscillator
  • FPAY 75.00
  • AKTX 31.51

About FPAY FlexShopper Inc.

FlexShopper Inc is a financial technology company engaged in providing certain types of durable goods to consumers on a lease-to-own basis and providing lease-to-own (LTO) terms to consumers of third-party retailers and e-tailers. Its products include electronics, computers, furniture, mattresses, cameras and camcorders, audio, musical instruments, health, fitness and sports, video games, homes, gardens and tools, appliances, and vacuums on a payment, lease basis. The firm generates a majority of its revenue by leasing its products. The company enables consumers utilizing its e-commerce marketplace to shop for brand-name electronics, home furnishings, and other durable goods on a lease-to-own (LTO) basis.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Share on Social Networks: